"Histopatologick\u00E1 klasifikace karcinomu prsu a jej\u00ED vztah k vyu\u017Eiteln\u00FDm modalit\u00E1m syst\u00E9mov\u00E9 l\u00E9\u010Dby" . "Breast cancer is a very heterogeneous group of tumours with a varying range of malignant potential, etiopathogenesis, prognosis and types of treatment. The traditional histopathological classification based on morphological appearance differentiates between the ductal, lobular and other cancers. The present stage of the targeted therapy results from the studies of expression relating to the hormone receptor, gene and protein profiles of tumours. Based on these profiles, breast cancers are divided into four basic groups - cancers with the luminal differentiation A, with the luminal differentiation B, HER2-positive tumours and what is known as \u201Etriple negative tumours\u201C. The presence or absence of expression of the hormone receptors and HER2-protein is the essential factor indicating the type of systemic treatment in the complex therapy for breast cancer, as well as chemotherapy, hormonal therapy and targeted biological therapy. The absence of expression of the hormone receptors and, on the other hand, overexpression of HER2-protein, are parameters which significantly influence the prognosis of the disease. They indicate that especially the group of cancers with basal differentiation, that is HER2-positive and triple negative, are prognostically unfavourable."@en . "Min\u00E1\u0159, Lubo\u0161" . "1" . "breast cancers"@en . "Histopathological classification of breast cancer in relation to the use the types of systemic treatment"@en . "[2F3551FAAF50]" . . "RIV/65269705:_____/12:#0001874" . . . "CZ - \u010Cesk\u00E1 republika" . "Jand\u00E1kov\u00E1, Eva" . . "Karcinom prsu p\u0159edstavuje zna\u010Dn\u011B heterogenn\u00ED skupinu n\u00E1dor\u016F s r\u016Fzn\u00FDm malign\u00EDm potenci\u00E1lem, etiopatogenez\u00ED, progn\u00F3zou i spektrem l\u00E9\u010Debn\u00FDch modalit. Tradi\u010Dn\u00ED histopatologick\u00E1 klasifikace, kter\u00E1 vych\u00E1z\u00ED z morfologick\u00E9ho vzhledu, d\u011Bl\u00ED karcinomy na dukt\u00E1ln\u00ED, lobul\u00E1rn\u00ED a ostatn\u00ED. Sou\u010Dasn\u00E1 etapa c\u00EDlen\u00E9 onkologick\u00E9 l\u00E9\u010Dby vych\u00E1z\u00ED ze studia exprese hormon\u00E1ln\u00EDch receptor\u016F a genov\u00E9ho a proteinov\u00E9ho expresn\u00EDho profilu n\u00E1dor\u016F. Na z\u00E1klad\u011B t\u011Bchto profil\u016F se malignity prsu d\u011Bl\u00ED na 4 z\u00E1kladn\u00ED skupiny \u2013 karcinomy s lumin\u00E1ln\u00ED diferenciac\u00ED A, s lumin\u00E1ln\u00ED diferenciac\u00ED B, n\u00E1dory HER2-pozitivn\u00ED a tzv. triple negativn\u00ED n\u00E1dory. P\u0159\u00EDtomnost \u010Di absence exprese hormon\u00E1ln\u00EDch receptor\u016F a HER2 proteinu je rozhoduj\u00EDc\u00EDm faktorem pro indikaci modalit syst\u00E9mov\u00E9 l\u00E9\u010Dby v r\u00E1mci komplexn\u00ED multimod\u00E1ln\u00ED terapie karcinomu prsu, tedy chemoterapie, hormon\u00E1ln\u00ED terapie a v neposledn\u00ED \u0159ad\u011B c\u00EDlen\u00E9 biologick\u00E9 l\u00E9\u010Dby. Absence exprese hormon\u00E1ln\u00EDch receptor\u016F, a naopak overexprese proteinu HER2 jsou parametry, kter\u00E9 v\u00FDrazn\u00FDm zp\u016Fsobem ovliv\u0148uj\u00ED progn\u00F3zu onemocn\u011Bn\u00ED. Z tohoto pohledu jsou prognosticky z\u00E1va\u017En\u00E9 p\u0159edev\u0161\u00EDm karcinomy ze skupiny s baz\u00E1ln\u00ED diferenciac\u00ED, tj. HER2-pozitivn\u00ED a triple negativn\u00ED." . . "1211-6645" . "Praktick\u00E1 gynekologie" . . . "Histopathological classification of breast cancer in relation to the use the types of systemic treatment"@en . "16" . . "Karcinom prsu p\u0159edstavuje zna\u010Dn\u011B heterogenn\u00ED skupinu n\u00E1dor\u016F s r\u016Fzn\u00FDm malign\u00EDm potenci\u00E1lem, etiopatogenez\u00ED, progn\u00F3zou i spektrem l\u00E9\u010Debn\u00FDch modalit. Tradi\u010Dn\u00ED histopatologick\u00E1 klasifikace, kter\u00E1 vych\u00E1z\u00ED z morfologick\u00E9ho vzhledu, d\u011Bl\u00ED karcinomy na dukt\u00E1ln\u00ED, lobul\u00E1rn\u00ED a ostatn\u00ED. Sou\u010Dasn\u00E1 etapa c\u00EDlen\u00E9 onkologick\u00E9 l\u00E9\u010Dby vych\u00E1z\u00ED ze studia exprese hormon\u00E1ln\u00EDch receptor\u016F a genov\u00E9ho a proteinov\u00E9ho expresn\u00EDho profilu n\u00E1dor\u016F. Na z\u00E1klad\u011B t\u011Bchto profil\u016F se malignity prsu d\u011Bl\u00ED na 4 z\u00E1kladn\u00ED skupiny \u2013 karcinomy s lumin\u00E1ln\u00ED diferenciac\u00ED A, s lumin\u00E1ln\u00ED diferenciac\u00ED B, n\u00E1dory HER2-pozitivn\u00ED a tzv. triple negativn\u00ED n\u00E1dory. P\u0159\u00EDtomnost \u010Di absence exprese hormon\u00E1ln\u00EDch receptor\u016F a HER2 proteinu je rozhoduj\u00EDc\u00EDm faktorem pro indikaci modalit syst\u00E9mov\u00E9 l\u00E9\u010Dby v r\u00E1mci komplexn\u00ED multimod\u00E1ln\u00ED terapie karcinomu prsu, tedy chemoterapie, hormon\u00E1ln\u00ED terapie a v neposledn\u00ED \u0159ad\u011B c\u00EDlen\u00E9 biologick\u00E9 l\u00E9\u010Dby. Absence exprese hormon\u00E1ln\u00EDch receptor\u016F, a naopak overexprese proteinu HER2 jsou parametry, kter\u00E9 v\u00FDrazn\u00FDm zp\u016Fsobem ovliv\u0148uj\u00ED progn\u00F3zu onemocn\u011Bn\u00ED. Z tohoto pohledu jsou prognosticky z\u00E1va\u017En\u00E9 p\u0159edev\u0161\u00EDm karcinomy ze skupiny s baz\u00E1ln\u00ED diferenciac\u00ED, tj. HER2-pozitivn\u00ED a triple negativn\u00ED."@cs . "Weinberger, V\u00EDt" . . . . . "I" . "Histopatologick\u00E1 klasifikace karcinomu prsu a jej\u00ED vztah k vyu\u017Eiteln\u00FDm modalit\u00E1m syst\u00E9mov\u00E9 l\u00E9\u010Dby"@cs . . . "RIV/65269705:_____/12:#0001874!RIV13-MZ0-65269705" . "3"^^ . "Histopatologick\u00E1 klasifikace karcinomu prsu a jej\u00ED vztah k vyu\u017Eiteln\u00FDm modalit\u00E1m syst\u00E9mov\u00E9 l\u00E9\u010Dby"@cs . "Histopatologick\u00E1 klasifikace karcinomu prsu a jej\u00ED vztah k vyu\u017Eiteln\u00FDm modalit\u00E1m syst\u00E9mov\u00E9 l\u00E9\u010Dby" . "139080" . "3"^^ . "6"^^ . .